Ryvu Therapeutics (RVU.WA) Osake Kurssi
Ryvu Therapeutics Kurssi
Liikevaihto on kasvanut 13,9 % vuodessa viimeisten 15 vuoden aikana 62,25 M PLN:een. Osakekohtainen tulos on laskenut 10,7 % vuodessa viimeisten 3 vuoden aikana. Ryvu Therapeuticsn nettomarginaali on nyt −162,6 %, noussut −706,9 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 32,64 PLN, eli yli nykyhintaa 90,4 %. 8 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Ryvu Therapeutics osakekurssi
Ryvu Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Ryvu Therapeutics -osakkeesta
Ryvu Therapeutics SA operates under a business model focused on developing innovative therapies to address unmet medical needs. They specialize in research and development of novel small molecule drugs targeting cancer and inflammatory diseases. As a biopharmaceutical company, Ryvu Therapeutics is dedicated to discovering and advancing potential treatments through rigorous scientific methods. By leveraging their expertise in drug discovery and understanding of disease biology, they strive to deliver breakthrough medicines that can improve patient outcomes. Ryvu Therapeutics aims to bring innovative therapies to market that have the potential to transform patient care in areas where medical needs are not yet met.
Ryvu Therapeutics SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Ryvu Therapeutics SA in the market include Genmab A/S, Incyte Corporation, and Gilead Sciences, Inc. These companies are also active in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies. However, Ryvu Therapeutics SA brings unique offerings to the market with its portfolio of proprietary drug candidates and therapeutic platforms. With its commitment to advancing precision oncology and targeted therapies, Ryvu Therapeutics SA distinguishes itself from its competitors and aims to make a significant impact in the field of biopharmaceuticals.
Ryvu Therapeutics SA is a biopharmaceutical company founded in 2007 in Poland. It focuses on discovering and developing innovative small molecule therapies for the treatment of various cancers. Ryvu Therapeutics SA has a strong research and development pipeline, with a particular emphasis on targeted therapies that can potentially address the underlying mechanisms driving cancer growth. The company has made significant progress in preclinical and early clinical stages, with several promising drug candidates. Ryvu Therapeutics SA aims to improve patient outcomes and contribute to the advancement of cancer treatment through its dedication to scientific excellence and innovative drug development approaches.
Ryvu Therapeutics SA has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2019, raising funds to support its research and development efforts. In October 2019, Ryvu Therapeutics SA entered into a collaboration agreement with an international pharmaceutical company for the development of innovative cancer therapies. Another noteworthy achievement is the advancement of its internal pipeline, particularly the progress made in the clinical development of its investigational drug candidates. These achievements demonstrate Ryvu Therapeutics SA's commitment to advancing novel therapies and establishing strategic partnerships in the field of oncology.
Ryvu Therapeutics SA is primarily present in Poland, where it is headquartered.
Ryvu Therapeutics SA is a biotechnology company that is committed to transforming patient care and addressing unmet medical needs. The company's corporate philosophy revolves around innovation, scientific excellence, and a patient-centric approach. Ryvu Therapeutics SA values the power of collaboration and partnerships, aiming to drive advancements in the field of oncology and rare diseases. With a focus on research and development, Ryvu Therapeutics SA strives to bring novel therapies to the market that have the potential to significantly improve and extend the lives of patients. This dedication to scientific discovery and a result-driven mindset defines the core values of Ryvu Therapeutics SA.
Analyytikot asettavat tällä hetkellä Ryvu Therapeutics-osakkeelle keskimääräisen tavoitehinnan 54,50 PLN (mediaani: 32,64 PLN), mikä merkitsee +218,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
8 analyytikkoa arvioi tällä hetkellä Ryvu Therapeutics-osaketta: 6 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Ryvu Therapeutics-yhtiöltä 130,37 M PLN liikevaihtoa ja −0,26 PLN osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Ryvu Therapeutics-osake noteerataan hintaan 3,91 EUR (17,14 PLN).
Ryvu Therapeutics-osake (RVU.WA) on listattuna 4 pörssissä, muun muassa: London (0RKT.L), Frankfurt (9Y4.F).
Ryvu Therapeutics SA is a research-driven biotechnology company focused on developing novel therapies for cancer and inflammatory diseases. The company collaborates closely with researchers and academics to make breakthrough discoveries in oncology research and translate them into clinical applications. The business model of Ryvu Therapeutics SA is based on combining innovative research with numerous partnerships with academic institutions to develop novel drugs that can be used against cancer and inflammatory diseases. The company's goal is to improve the lives of cancer patients and expand the boundaries of medicine through the development of innovative technologies and new treatment options. To achieve this, the company has a wide range of products in the pipeline, including small molecule inhibitors, biologics, and immunotherapies. In addition to developing new treatment options, Ryvu Therapeutics SA also works closely with academic institutions to make new discoveries in oncology research and translate them into clinical applications. The company aims to attract new partners and investors to expand its business model and venture into new therapy areas. Overall, Ryvu Therapeutics SA's business model offers a wide range of products and services tailored to the needs of cancer patients. The company combines innovative research with numerous partnerships with academic institutions to make groundbreaking discoveries in oncology research and translate them into clinical applications. With a wide range of products in the pipeline and a dedicated leadership team, Ryvu Therapeutics SA is well positioned to improve the lives of cancer patients and promote the growth of the company.
odotettu liikevaihto Ryvu Therapeutics on 130,37 M PLN. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Ryvu Therapeutics on −6,03 M PLN. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Ryvu Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −65,67. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Ryvu Therapeutics-osakkeen arvostusta.
Ryvu Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,04. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Ryvu Therapeutics-osakkeen arvostuskennuslukuna.
Ryvu Therapeutics:n Eulpool-laatuscore on 2/10.
Ryvu Therapeutics:n ISIN on PLSELVT00013. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Ryvu Therapeutics:n WKN on A1JUH2. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Ryvu Therapeutics:n ticker on RVU.WA. Tämä pörssinoteeraus käytetään Ryvu Therapeutics-osakkeiden kauppaan pörssissä.
Ryvu Therapeutics osake
Kaikki tunnusluvut ja syvällinen analyysi Ryvu Therapeutics:sta
Meidän osakeanalyysimme Ryvu Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Ryvu Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: